As of November 6, 2026, one holder's latest Schedule 13D or 13G filing report owning 5% or more of Fulgent Genetics, Inc. The largest reported stake is Ming Hsieh's, at 32.26%. 5 filings are on record since July 29, 2025 (Schedule 13D/A, May 27, 2026).
Sell to companies like Fulgent Genetics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Holder: Ming Hsieh · Percent: 32.26% · SCHEDULE 13D/A
- · Holder: Ming Hsieh · Percent: 30.74% · SCHEDULE 13D/A
- · Holder: Integrated Core Strategies (US) LLC · Percent: 3% · SCHEDULE 13G/A
- · Holder: Millennium Management LLC · Percent: 4.7% · SCHEDULE 13G/A
- · Holder: Millennium Management LLC · Percent: 5.6% · SCHEDULE 13G/A
Fulgent Genetics, Inc. has 5 Schedule 13D or 13G filings on record since 2025-07-29. 1 holder's latest filing reports 5% or more of common stock, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| 32.26% | 8,872,539 | SCHEDULE 13D/A, 2026-05-27 | 2026-05-22 | |
| Integrated Core Strategies (US) LLC | 3% | 918,503 | SCHEDULE 13G/A, 2026-02-04 | 2025-12-31 |
Holding shares or following this stake? See who's behind Fulgent Genetics, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Fulgent Genetics, Inc. and the records around it.
Fulgent Genetics, Inc. elsewhere on the record
Companies that share a holder
- Integrated Core Strategies (US) LLC also filed stake reports on 121 other companies: StepStone Group Inc. (Nov 2026), Catalyst Acquisition Corp. (Nov 2026), RxSight, Inc. (Nov 2026)
Watch Fulgent Genetics, Inc.
Get an email when Fulgent Genetics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Fulgent Genetics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Fulgent Genetics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Fulgent Genetics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
5 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Purpose of Transaction (Item 4)
Ming Hsieh
The Reporting Person holds the shares of Common Stock reported in this Statement for general investment purposes. The Reporting Person may, from time to time, acquire additional, or dispose of, shares of Common Stock or other securities of the Issuer, in the Reporting Person's capacity as Chief Executive Officer and Chairperson of the Board of the Issuer or otherwise, or engage in discussions with the Issuer concerning investments in the Issuer. The Reporting Person intends to review his ownership of Common Stock (including shares of Common Stock held through the Trust) on a continuing basis and, depending upon the price and availability of shares of Common Stock of the Issuer, subsequent developments affecting the Issuer, the Issuer's business and prospects, other investment and business opportunities available to the Reporting Person, general stock market and economic conditions, tax considerations and other factors considered relevant, the Reporting Person may decide at any time to increase or to decrease the size of his holdings of the Issuer's securities or securities derived of, exercisable for or convertible into the Issuer's securities.Item 4 of the SCHEDULE 13D/A filed 2026-05-27
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-29 | Millennium Management LLC | 4.7% | SCHEDULE 13G/A |
| 2025-07-29 | Millennium Management LLC | 5.6% | SCHEDULE 13G/A |
| 2026-02-04 | Integrated Core Strategies (US) LLC | 3% | SCHEDULE 13G/A |
| 2026-03-31 | Ming Hsieh | 30.74% | SCHEDULE 13D/A |
| 2026-05-27 | Ming Hsieh | 32.26% | SCHEDULE 13D/A |
Questions about who owns Fulgent Genetics, Inc.
Who owns Fulgent Genetics, Inc.?
On this page, one holder's latest ownership filing reports 5% or more of Fulgent Genetics, Inc.: Ming Hsieh (32.26%, Schedule 13D/A, filed 2026-05-27).
When did Ming Hsieh buy into Fulgent Genetics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Ming Hsieh on this page is the Schedule 13D/A, filed 2026-03-31, reporting 30.74%; its latest, Schedule 13D/A filed 2026-05-27, reports 32.26%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 5 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Fulgent Genetics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.